Jaguar8 commented on a stock · Jul 26, 2024 09:38

NEWS: California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) $8M

Immix Biopharma (Nasdaq: IMMX) has been awarded an $8 million CLIN2 grantfrom the California Institute for Regenerative Medicine (CIRM) to support the clinical development of NXC-201, a CAR-T cell therapy for relapsed/refractory AL Amyloidosis. The funding will be used for the NEXICART-2 U.S. clinical trial, which aims to evaluate the safety and efficacy of NXC-201 in patients with adequate cardiac function who have not received prior BCMA-targeted therapy.

The decision follows promising results from the ex-U.S. NEXICART-1 study, which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients. NXC-201 is currently the only CAR-T therapy in development for AL Amyloidosis, a rare disease with treatment options. The therapy's potential has been recognized in a recent New England Journal of Medicine review article.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

6039 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8164

Followers

Following

93K

Visitors